Artificial intelligence halves development time for cancer drug

A new cancer drug is being brought to market following testing by a pharmaceutical start-up using artificial intelligence that halved the usual time in development. Berg Health expects the drug to be available within three years, seven years after it was put into development. This is half of the usual timeframe of 14 years and has been achieved using a specialised form of artificial intelligence that compares patient samples. Niven Narain, president, chief technology officer and co-founder of Berg, said: “What the AI platform has done is helped us to develop this drug by understanding that the key hallmark of cancer is the cancer metabolism.” Cancer cell metabolism has been an area of interest for the National Institutes of Health (NIH) in recent times, and Berg’s drug will undergo preclinical…

Link to Full Article: Artificial intelligence halves development time for cancer drug

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!